About Qlaris Bio
Qlaris Bio is a company based in United States founded in 2019 by Thurein Htoo. Qlaris Bio has raised $58.62 million across 4 funding rounds from investors including Mayo Clinic, New Leaf Venture Partners and abrdn. Qlaris Bio offers products and services including QLS-111. Qlaris Bio operates in a competitive market with competitors including TearClear, 4B Technologies, Mannin Research, Aria Pharmaceuticals and Visiox Pharma, among others.
- Headquarter United States
- Founders Thurein Htoo
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Qlaris Bio, Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$58.62 M (USD)
in 4 rounds
-
Latest Funding Round
$3.95 M (USD), Series B
Jun 12, 2026
-
Investors
Mayo Clinic
& 4 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Qlaris Bio
Qlaris Bio offers a comprehensive portfolio of products and services, including QLS-111.
Lowers intraocular pressure for glaucoma and ocular hypertension.
People of Qlaris Bio
Unlock access to complete
Unlock access to complete
Funding Insights of Qlaris Bio
Qlaris Bio has successfully raised a total of $58.62M across 4 strategic funding rounds. The most recent funding activity was a Series B round of $3.95 million completed in June 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Qlaris Bio
Qlaris Bio has secured backing from 5 investors, including venture fund and institutional investors. Prominent investors backing the company include Mayo Clinic, New Leaf Venture Partners and abrdn.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Canaan is recognized as an early-stage venture capital firm.
|
Locked | Locked | Locked | |
|
Stage-agnostic investments in US life sciences are managed.
|
Locked | Locked | Locked | |
|
Multiple sectors are invested in by abrdn's private equity fund.
|
Locked | Locked | Locked |
Investor details for Qlaris Bio
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Qlaris Bio
Investment portfolio details for Qlaris Bio
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Qlaris Bio
Detailed financials for Qlaris Bio
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Qlaris Bio Comparisons
Peer comparison for Qlaris Bio
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Qlaris Bio
Qlaris Bio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as TearClear, 4B Technologies, Mannin Research, Aria Pharmaceuticals and Visiox Pharma, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Filter technology for preservative-free ophthalmic drugs is developed.
|
|
| Locked | Locked | Locked |
Drugs for neurological disorders including ALS and Alzheimer's are developed.
|
|
| Locked | Locked | Locked |
Therapeutics for vascular diseases are developed by Mannin Research.
|
|
| Locked | Locked | Locked |
Develops innovative drug technologies for multiple diseases.
|
|
| Locked | Locked | Locked |
Therapeutics for ophthalmic diseases including glaucoma are developed.
|
Detailed competitors of Qlaris Bio
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Qlaris Bio
Complete news archive for Qlaris Bio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Qlaris Bio
Qlaris Bio was founded in 2019.
Qlaris Bio is headquartered in United States.
Thurein Htoo is the current CEO of Qlaris Bio. They have also founded this company.
Qlaris Bio is a funded company, having raised a total of $58.62M across 4 funding rounds to date.
Qlaris Bio was founded in 2019 in the United States within the biotechnology sector. AI-based technology is utilized by the company to address ophthalmic diseases. A joint venture is maintained with Mayo Clinic and nference to support development efforts. The lead candidate, QLS-101, is advanced in the preclinical stage for managing intraocular pressure disturbances, a sight-threatening progressive rare disease in pediatrics.
Qlaris Bio's top competitors include 4B Technologies, Visiox Pharma and TearClear.
Qlaris Bio offers QLS-111.
Qlaris Bio has 5 investors. Key investors include Mayo Clinic, New Leaf Venture Partners, abrdn, Canaan, and Correlation Ventures.